|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Department of Hematology/Oncology, University
of Leipzig, Germany; and the Department of Haematology, Imperial
College School of Medicine, Hammersmith Hospital, London, United
Kingdom.
Chronic myeloid leukemia (CML) is probably the most
extensively studied human malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first consistent
chromosomal abnormality associated with a specific type of leukemia was
a breakthrough in cancer biology. It took 13 years before it was
appreciated that the Ph chromosome is the result of a t(9;22)
reciprocal chromosomal translocation2 and another 10 years
before the translocation was shown to involve the ABL
proto-oncogene normally on chromosome 93 and a previously
unknown gene on chromosome 22, later termed BCR for
breakpoint cluster region.4 The deregulated Abl tyrosine kinase activity was then defined as the pathogenetic
principle,5 and the first animal models were
developed.6 The end of the millennium sees all this
knowledge transferred from the bench to the bedside with the arrival of
Abl-specific tyrosine kinase inhibitors that selectively inhibit the
growth of BCR-ABL-positive cells in vitro7,8
and in vivo.9 In this review we will try to summarize what is currently known
about the molecular biology of CML. Because several aspects of CML
pathogenesis may be attributable to the altered function of the 2 genes
involved in the Ph translocation, we will also address the
physiological roles of BCR and ABL. We concede
that a review of this nature can never be totally comprehensive without losing clarity, and we therefore apologize to any authors whose work we
have not cited. The ABL gene is the human homologue of the
v-abl oncogene carried by the Abelson murine leukemia virus
(A-MuLV),10 and it encodes a nonreceptor tyrosine
kinase.11 Human Abl is a ubiquitously expressed 145-kd
protein with 2 isoforms arising from alternative splicing of the first
exon.11 Several structural domains can be defined within
the protein (Figure 1). Three SRC
homology domains (SH1-SH3) are located toward the NH2
terminus. The SH1 domain carries the tyrosine kinase function, whereas
the SH2 and SH3 domains allow for interaction with other
proteins.12 Proline-rich sequences in the center of the
molecule can, in turn, interact with SH3 domains of other proteins,
such as Crk.13 Toward the 3' end, nuclear localization
signals14 and the DNA-binding15 and
actin-binding motifs16 are found.
Several fairly diverse functions have been attributed to Abl, and the
emerging picture is complex. Thus, the normal Abl protein is involved
in the regulation of the cell cycle,17,18 in the cellular
response to genotoxic stress,19 and in the transmission of
information about the cellular environment through integrin signaling.20 (For a comprehensive review of Abl function,
see Van Etten21). Overall, it appears that the Abl protein
serves a complex role as a cellular module that integrates signals from various extracellular and intracellular sources and that influences decisions in regard to cell cycle and apoptosis. It must be stressed, however, that many of the data are based solely on in vitro studies in
fibroblasts, not hematopoietic cells, and are still controversial. Unfortunately, the generation of ABL knockout mice failed to
resolve most of the outstanding issues.22,23
The 160-kd Bcr protein, like Abl, is ubiquitously
expressed.11 Several structural motifs can be delineated
(Figure 2). The first N-terminal exon
encodes a serine-threonine kinase. The only substrates of this kinase
identified so far are Bap-1, a member of the 14-3-3 family of
proteins,24 and possibly Bcr itself.11 A
coiled-coil domain at the N-terminus of Bcr allows dimer formation in
vivo.25 The center of the molecule contains a region with dbl-like and pleckstrin-homology (PH) domains that stimulate
the exchange of guanidine triphosphate (GTP) for guanidine diphosphate (GDP) on Rho guanidine exchange factors,26 which in turn
may activate transcription factors such as NF-
The breakpoints within the ABL gene at 9q34 can occur
anywhere over a large (greater than 300 kb) area at its 5' end, either upstream of the first alternative exon Ib, downstream of the second alternative exon Ia, or, more frequently, between the
two35 (Figure 3). Regardless
of the exact location of the breakpoint, splicing of the primary hybrid
transcript yields an mRNA molecule in which BCR sequences
are fused to ABL exon a2. In contrast to ABL,
breakpoints within BCR localize to 1 of 3 so-called
breakpoint cluster regions (bcr). In most patients with CML
and in approximately one third of patients with Ph-positive acute
lymphoblastic leukemia (ALL), the break occurs within a 5.8-kb area
spanning BCR exons 12-16 (originally referred to as exons
b1-b5), defined as the major breakpoint cluster region
(M-bcr). Because of alternative splicing, fusion transcripts
with either b2a2 or b3a2 junctions can be formed. A 210-kd chimeric
protein (P210BCR-ABL) is derived from this mRNA.
In the remaining patients with ALL and rarely in patients with CML,
characterized clinically by prominent monocytosis,36,37
the breakpoints are further upstream in the 54.4-kb region between the
alternative BCR exons e2' and e2, termed the minor
breakpoint cluster region (m-bcr). The resultant e1a2 mRNA
is translated into a 190-kd protein
(P190BCR-ABL). Recently, a third breakpoint
cluster region (µ-bcr) was identified downstream of exon
19, giving rise to a 230-kd fusion protein (P230BCR-ABL) associated with the rare
Ph-positive chronic neutrophilic leukemia,38 though not in
all cases.39 If sensitive techniques such as nested reverse transcription-polymerase chain reaction are used, transcripts with the e1a2 fusion are detectable in many patients with classical P210BCR-ABL CML.40 The low level of
expression of these P190-type transcripts compared to P210 indicates
that they are most likely the result of alternative splicing of the
primary mRNA. Occasional cases with other junctions, such as b2a3,
b3a3, e1a3, e6a2,41 or e2a2,42 have been
reported in patients with ALL and CML. These "experiments of
nature" provide important information as to the function of the
various parts of BCR and ABL in the oncogenic
fusion protein. Interestingly, ABL exon 1, even if retained
in the genomic fusion, is never part of the chimeric mRNA. Thus, it
must be spliced out during processing of the primary mRNA; the
mechanism underlying this apparent peculiarity is unknown. Based on the
observation that the Abl part in the chimeric protein is almost
invariably constant while the Bcr portion varies greatly, one may
deduce that Abl is likely to carry the transforming principle whereas the different sizes of the Bcr sequence may dictate the phenotype of
the disease. In support of this notion, rare cases of ALL express a
TEL-ABL fusion gene,43,44 indicating that the
BCR moiety can in principle be replaced by other sequences
and still cause leukemia. Interestingly, a fusion between
TEL(ETV6) and the ABL-related gene ARG
has recently been described in a patient with AML.45 Although all 3 major Bcr-Abl fusion proteins induce a CML-like disease
in mice, they differ in their ability to induce lymphoid leukemia,46 and, in contrast to P190 and P210,
transformation to growth factor independence by P230BCR-ABL
is incomplete,47 which is consistent with the relatively
benign clinical course of P230-positive chronic neutrophilic
leukemia.38
One of the most intriguing questions relates to the events responsible
for the chromosomal translocation in the first place. From
epidemiologic studies it is well known that exposure to ionizing radiation (IR) is a risk factor for CML.48,49 Moreover,
BCR-ABL fusion transcripts can be induced in hematopoietic
cells by exposure to IR in vitro50; such IR-induced
translocations may not be random events but may depend on the cellular
background and on the particular genes involved. Two recent reports
showed that the physical distance between the BCR and the
ABL genes in human lymphocytes51 and
CD34+ cells52 is shorter than might be
expected by chance; such physical proximity could favor translocation
events involving the 2 genes. However, the presence of the
BCR-ABL translocation in a hematopoietic cell is not in
itself sufficient to cause leukemia because BCR-ABL fusion
transcripts of M-bcr and m-bcr type are
detectable at low frequency in the blood of many healthy
individuals.53,54 It is unclear why Ph-positive leukemia
develops in a tiny minority of these persons. It may be that the
translocation occurs in cells committed to terminal differentiation
that are thus eliminated or that an immune response suppresses or
eliminates Bcr-Abl-expressing cells. Indirect evidence that such a
mechanism may be relevant comes from the observation that certain HLA
types protect against CML.55 Another possibility is that
BCR-ABL is not the only genetic lesion required to induce
chronic-phase CML. Indeed, a skewed pattern of G-6PD isoenzymes has
been detected in Ph-negative Epstein-Barr virus-transformed
B-cell lines derived from patients with CML, suggesting that a
Ph-negative pathologic state may precede the emergence of the Ph
chromosome.56
Essential features of the Bcr-Abl protein
Deregulation of the Abl tyrosine kinase
A host of substrates can be tyrosine phosphorylated by
Bcr-Abl (Table 1).
Most important, because of autophosphorylation, there is a marked
increase of phosphotyrosine on Bcr-Abl itself, which creates
binding sites for the SH2 domains of other proteins. Generally,
substrates of Bcr-Abl can be grouped according to their physiologic role into adapter molecules (such as Crkl and
p62DOK), proteins associated with the organization of the
cytoskeleton and the cell membrane (such as paxillin and talin), and
proteins with catalytic function (such as the nonreceptor tyrosine
kinase Fes or the phosphatase Syp). It is important to note that the choice of substrates depends on the cellular context. For example, Crkl
is the major tyrosine-phosphorylated protein in CML
neutrophils,73 whereas phosphorylated p62DOK
is predominantly found in early progenitor cells.74
Tyrosine phosphatases counterbalance and regulate the effects of
tyrosine kinases under physiologic conditions, keeping cellular phosphotyrosine levels low. Two tyrosine phosphatases,
Syp83 and PTP1B,84 have been shown to form
complexes with Bcr-Abl, and both appear to dephosphorylate Bcr-Abl.
Interestingly, PTP1B levels increase in a kinase-dependent manner,
suggesting that the cell attempts to limit the impact of Bcr-Abl
tyrosine kinase activity. At least in fibroblasts, transformation by
Bcr-Abl is impaired by the overexpression of PTP1B.85
Interestingly, we recently observed the up-regulation of receptor
protein tyrosine phosphatase Activated signaling pathways and biologic properties of BCR-ABL-positive cells Three major mechanisms have been implicated in the malignant transformation by Bcr-Abl, namely altered adhesion to stroma cells and extracellular matrix,87 constitutively active mitogenic signaling88 and reduced apoptosis89 (Figure 5). A fourth possible mechanism is the recently described proteasome-mediated degradation of Abl inhibitory proteins.66
Altered adhesion properties CML progenitor cells exhibit decreased adhesion to bone marrow stroma cells and extracellular matrix.87,90 In this scenario, adhesion to stroma negatively regulates cell proliferation, and CML cells escape this regulation by virtue of their perturbed adhesion properties. Interferon- (IFN-), an active therapeutic agent in CML, appears to reverse the adhesion defect.91
Recent data suggest an important role for  -integrins in the
interaction between stroma and progenitor cells. CML cells express an
adhesion-inhibitory variant of 1 integrin that is not found in
normal progenitors.92 On binding to their receptors,
integrins are capable of initiating normal signal transduction from
outside to inside93; it is thus conceivable that the
transfer of signals that normally inhibit proliferation is impaired in
CML cells. Because Abl has been implicated in the intracellular
transduction of such signals, this process may be further disturbed by
the presence of a large pool of Bcr-Abl protein in the cytoplasm.
Furthermore, Crkl, one of the most prominent tyrosine-phosphorylated
proteins in Bcr-Abl-transformed cells,73 is involved in
the regulation of cellular motility94 and in integrin-mediated cell adhesion95 by association with
other focal adhesion proteins such as paxillin, the focal adhesion
kinase Fak, p130Cas,96 and Hef1.97 We
recently demonstrated that Bcr-Abl tyrosine kinase up-regulates the
expression of 6 integrin mRNA,86 which points to
transcriptional activation as yet another possible mechanism by which
Bcr-Abl may have an impact on integrin signaling. Thus, though there is
sound evidence that Bcr-Abl influences integrin function, it is more
difficult to determine the precise nature of the biologic consequences,
and, at least in certain cellular systems, integrin function appears to
be enhanced rather than reduced by Bcr-Abl.98
Activation of mitogenic signaling Ras and the MAP kinase pathways.
Several links between Bcr-Abl and Ras have been defined.
Autophosphorylation of tyrosine 177 provides a docking site for the adapter molecule Grb-2.57 Grb-2, after binding to the Sos
protein, stabilizes Ras in its active GTP-bound form. Two other adapter molecules, Shc and Crkl, can also activate Ras. Both are substrates of
Bcr-Abl73,99 and bind Bcr-Abl through their SH2 (Shc) or SH3 (Crkl) domains. The relevance of Ras activation by Crkl is, however, questionable because it appears to be restricted to
fibroblasts.100 Moreover, direct binding of Crkl to
Bcr-Abl is not required for the transformation of myeloid
cells.101 Circumstantial evidence that Ras activation is
important for the pathogenesis of Ph-positive leukemias comes from the
observation that activating mutations are uncommon, even in the blastic
phase of the disease,102 unlike in most other tumors. This
implies that the Ras pathway is constitutively active, and no further
activating mutations are required. There is still dispute as to which
mitogen-activated protein (MAP) kinase pathway is downstream of Ras in
Ph-positive cells. Stimulation of cytokine receptors such as IL-3 leads
to the activation of Ras and the subsequent recruitment of the
serine-threonine kinase Raf to the cell membrane.103 Raf
initiates a signaling cascade through the serine-threonine kinases
Mek1/Mek2 and Erk, which ultimately leads to the activation of gene
transcription.104 Although some data indicate that this
pathway may be activated only in v-abl- but not in
BCR-ABL-transformed cells,105 this view has recently been
challenged.106 Moreover, activation of the Jnk/Sapk
pathway by Bcr-Abl has been demonstrated and is required for malignant
transformation107; thus, signaling from Ras may be
relayed through the GTP-GDP exchange factor Rac108 to
Gckr (germinal center kinase related)109 and further down
to Jnk/Sapk (Figure 6). There is also
some evidence that p38, the third pillar of the MAP kinase pathway, is
also activated in BCR-ABL-transformed cells, and there are other
pathways with mitogenic potential. In any case, the signal is
eventually transduced to the transcriptional machinery of the
cell.
It is also possible that Bcr-Abl uses growth factor pathways in a more direct way. For example, association with the c subunit of the IL-3
receptor110 and the Kit receptor111 has been
observed. Interestingly, the pattern of tyrosine-phosphorylated
proteins seen in normal progenitor cells after stimulation with Kit
ligand is similar to the pattern seen in CML progenitor
cells.112 Dok-1 (p62DOK), one of the most
prominent phosphoproteins in this setting, forms complexes with Crkl,
RasGAP, and Bcr-Abl. In fact, there may be a whole family of related
proteins with similar functions for example, the recently described
Dok-2 (p56DOK2).113 Somewhat surprisingly,
p62DOK is essential for transformation of Rat-1 fibroblasts
but not for growth-factor independence of myeloid
cells114; thus, its true role remains to be defined.
Jak-Stat pathway. The first evidence for involvement of the Jak-Stat pathway came from studies in v-abl-transformed B cells.62 Constitutive phosphorylation of Stat transcription factors (Stat1 and Stat5) has since been reported in several BCR-ABL-positive cell lines115 and in primary CML cells,116 and Stat5 activation appears to contribute to malignant transformation.117 Although Stat5 has pleiotropic physiologic functions,118 its effect in BCR-ABL-transformed cells appears to be primarily anti-apoptotic and involves transcriptional activation of Bcl-xL.119,120 In contrast to the activation of the Jak-Stat pathway by physiologic stimuli, Bcr-Abl may directly activate Stat1 and Stat5 without prior phosphorylation of Jak proteins. There seems to be specificity for Stat6 activation by P190BCR-ABL proteins as opposed to P210BCR-ABL.115 It is tempting to speculate that the predominantly lymphoblastic phenotype in these leukemias is related to this peculiarity. The role of the Ras and Jak-Stat pathways in the cellular response to growth factors could explain the observation that BCR-ABL renders a number of growth factor-dependent cell lines factor independent.105,121 In some experimental systems there is evidence for an autocrine loop dependent on the Bcr-Abl-induced secretion of growth factors,122 and it was recently reported that Bcr-Abl induces an IL-3 and G-CSF autocrine loop in early progenitor cells.123 Interestingly, Bcr-Abl tyrosine kinase activity may induce expression not only of cytokines but also of growth factor receptors such as the oncostatin M receptor.86 One should bear in mind, however, that during
the chronic phase, CML progenitor cells are still dependent on external
growth factors for their survival and proliferation,124 though less than normal progenitors.125 A recent study
sheds fresh light on this issue. FDCPmix cells transduced with a
temperature-sensitive mutant of BCR-ABL have a reduced
requirement for growth factors at the kinase permissive temperature
without differentiation block.126 This situation resembles
chronic-phase CML, in which the malignant clone has a subtle growth
advantage while retaining almost normal differentiation capacity.
PI3 kinase pathway. PI3 kinase activity is required for the proliferation of BCR-ABL-positive cells.127 Bcr-Abl forms multimeric complexes with PI3 kinase, Cbl, and the adapter molecules Crk and Crkl,95 in which PI3 kinase is activated. The next relevant substrate in this cascade appears to be the serine-threonine kinase Akt.128 This kinase had previously been implicated in anti-apoptotic signaling.129 A recent report placed Akt in the downstream cascade of the IL-3 receptor and identified the pro-apoptotic protein Bad as a key substrate of Akt.130 Phosphorylated Bad is inactive because it is no longer able to bind anti-apoptotic proteins such as BclXL and it is trapped by cytoplasmic 14-3-3 proteins. Altogether this indicates that Bcr-Abl might be able to mimic the physiologic IL-3 survival signal in a PI3 kinase-dependent manner (see also below). Ship131 and Ship-2,132 2 inositol phosphatases with somewhat different specificities, are activated in response to growth factor signals and by Bcr-Abl. Thus, Bcr-Abl appears to have a profound effect on phosphoinositol metabolism, which might again shift the balance to a pattern similar to physiologic growth factor stimulation. Myc pathway. Overexpression of Myc has been demonstrated in many human malignancies. It is thought to act as a transcription factor, though its target genes are largely unknown. Activation of Myc by Bcr-Abl is dependent on the SH2 domain, and the overexpression of Myc partially rescues transformation-defective SH2 deletion mutants whereas the overexpression of a dominant-negative mutant suppresses transformation.133 The pathway linking Myc to the SH2 domain of Bcr-Abl is still unknown. However, results obtained in v-abl-transformed cells suggest that the signal is transduced through Ras/Raf, cyclin-dependent kinases (cdks), and E2F transcription factors that ultimately activate the MYC promoter.134 Similar results were reported for BCR-ABL-transformed murine myeloid cells.135 How these findings relate to human Ph-positive cells is unknown. It seems likely that the effects of Myc in Ph-positive cells are probably not different from those in other tumors. Depending on the cellular context, Myc may constitute a proliferative or an apoptotic signal.136,137 It is therefore likely that the apoptotic arm of its dual function is counterbalanced in CML cells by other mechanisms, such as the PI3 kinase pathway. Inhibition of apoptosis Expression of Bcr-Abl in factor-dependent murine138 and human122 cell lines prevents apoptosis after growth-factor withdrawal, an effect that is critically dependent on tyrosine kinase activity and that correlates with the activation of Ras.88,139 Moreover, several studies showed that BCR-ABL-positive cell lines are resistant to apoptosis induced by DNA damage.89,140 The underlying biologic mechanisms are still not well understood. Bcr-Abl may block the release of cytochrome C from the mitochondria and thus the activation of caspases.141,142 This effect upstream of caspase activation might be mediated by the Bcl-2 family of proteins. Bcr-Abl has been shown to up-regulate Bcl-2 in a Ras-143 or a PI3 kinase-dependent128 manner in Baf/3 and 32D cells, respectively. Moreover, as mentioned previously, BclxL is transcriptionally activated by Stat5 in BCR-ABL-positive cells.119,120Another link between BCR-ABL and the inhibition of apoptosis
might be the phosphorylation of the pro-apoptotic protein Bad. In
addition to Akt, Raf-1, immediately downstream of Ras, phosphorylates Bad on 2 serine residues.144,145 Two recent studies
provided evidence that the survival signal provided by Bcr-Abl is at
least partially mediated by Bad and requires targeting of Raf-1 to the mitochondria.146,147 It is also possible that Bcr-Abl
inhibits apoptosis by down-regulating interferon consensus sequence
binding protein (ICSBP).148,149 These data are interesting
because ICSBP knockout mice develop a myeloproliferative
syndrome,150 and hematopoietic progenitor cells from
ICSBP It becomes clear that the multiple signals initiated by Bcr-Abl have
proliferative and anti-apoptotic qualities that are frequently difficult to separate. Thus, Bcr-Abl may shift the balance toward the
inhibition of apoptosis while simultaneously providing a proliferative stimulus. This is in line with the concept that a proliferative signal
leads to apoptosis unless it is counterbalanced by an anti-apoptotic signal,152 and Bcr-Abl fulfills both requirements at the
same time. There is, however, controversy. One report found 32D cells transfected with BCR-ABL to be more sensitive to IR than the
parental cells,153 whereas 2 other studies failed to
detect any difference between CML and normal primary progenitor cells
with regard to their sensitivity to IR and growth factor
withdrawal.124,154 Furthermore, based on results obtained
in transfected cell systems, it was suggested that Bcr-Abl inhibits
apoptosis mediated by the Fas receptor/Fas ligand
system.155 However, though there may be a role for this
system in mediating the clinical response to interferon- Degradation of inhibitory proteins. The recent discovery that Bcr-Abl induces the proteasome-mediated degradation of Abi-1 and Abi-2,66 2 proteins with inhibitory function, may be the first indication of yet another way by which Bcr-Abl induces cellular transformation. Most compelling, the degradation of Abi-1 and Abi-2 is specific for Ph-positive acute leukemias and is not seen in Ph-negative samples of comparable phenotype. The overall significance of this observation remains to be seen, and one must bear in mind that the data refer to acute leukemias and not to chronic phase CML. It is nevertheless tempting to speculate that other proteins, whose level of expression is regulated through the proteasome pathway, may also be degraded. A good candidate would be the cell cycle inhibitor p27, but to our knowledge no data are available yet.
Various experimental systems have been developed to study the pathophysiology of CML. All of them have their advantages and shortcomings, and it is probably fair to say that there is still no ideal in vitro or in vivo model that would cover all aspects of the human disease. Cell lines Fibroblasts.
Fibroblast lines have been used extensively in CML research because
they are easy to manipulate. Fibroblast transformation Hematopoietic cell lines. Until relatively recently, only a few BCR-ABL-positive lines derived from CML were available, but their number has grown considerably in the past few years.164 They include cell lines with myeloid differentiation, such as the well-known K562, and lymphoid phenotype, such as BV173. The main drawback common to all these lines is the fact that they are derived from blast crisis and, thus, contain genetic lesions in addition to BCR-ABL. Consequently, they may reflect blast crisis fairly well but are insufficient models of chronic phase CML. Until now, no cell line from chronic phase CML has been established, just as no cell line could be derived from normal human bone marrow. Even attempts to immortalize Ph-positive B-cells from patients in the chronic phase of disease were not successful because these lines have a limited life span,165 in contrast to their Ph-negative counterparts. One could therefore speculate that the very establishment of a line from a patient with CML would be diagnostic of advanced disease. In this context, it is surprising that most human CML lines remain dependent on Bcr-Abl tyrosine kinase activity for their proliferation and survival, as shown by their susceptibility to the effects of the Abl-specific tyrosine kinase inhibitor STI571.8 However, the phenotype of these cell lines is that of an acute leukemia. Therefore great caution is warranted if experimental results are to be transferred to chronic phase CML. A striking example is the fact that inhibition of apoptosis by Bcr-Abl is easily demonstrable in cell lines139 but not in primary cells.124 It should also be noted that many of the lines used have undergone hundreds, if not thousands, of rounds of replication, and different laboratories frequently house lines that have little in common but their names and BCR-ABL positivity. Transformation of factor-dependent cell lines to growth-factor independence is an important feature of Bcr-Abl, and, in fact, other oncoproteins that contain an activated tyrosine kinase.43,166 Although it is usually difficult to obtain stable expression of BCR-ABL in previously immortalized cell lines, this is relatively easily achieved in factor-dependent lines, presumably because BCR-ABL expression is an advantage to the latter but useless or even detrimental to the former. Murine cell lines such as Baf/3 and 32D and human cell lines such as MO7 were used to study the effects of BCR-ABL by direct comparison between transduced and parental cells. A particular advantage of the murine lines is the fact that they are derived from normal nonmalignant hematopoietic cells. Unfortunately, this does not rule out the development of additional mutations167 that confer a selective growth advantage. Furthermore, it is not clear how the transformation to complete factor independence relates to clinical CML in which the cells are still factor-dependent, though obviously less so than normal hematopoietic cells.123 The subject of growth factor independence and BCR-ABL transformation has been reviewed recently.168 None of the cell lines mentioned above is capable of multilineage hematopoietic differentiation. Two strategies are promising in overcoming this restraint. A recent report126 shows that murine FDCPmix cells, transduced with a temperature-sensitive mutant of BCR-ABL, become partially factor-independent at the permissive temperature, in analogy to chronic phase CML. They retain the capacity for terminal differentiation, similar to chronic phase CML cells. Another approach is the study of embryonic stem (ES) cells transduced with BCR-ABL. In one such experimental system, it was possible to reproduce one cardinal feature of the clinical disease in the model, namely the expansion of the myeloid compartment at the expense of the erythroid compartment.169 Interestingly, the increase in total cell numbers in the BCR-ABL-transduced ES cells was found to result from increased proliferation though there was little effect on apoptosis, another finding in line with observations in primary Ph-positive cells.124,154 In this system, a stromal cell layer is used on which the ES cells removed from leukemia-inhibitory factor (LIF) differentiate into hemangioblasts and then into hematopoietic cells. This may explain why these results are not strictly comparable to those of another study, in which BCR-ABL resulted in the decreased formation of embryonal bodies along with increased output of all kinds of hematopoietic progenitors.170 In yet another study, BCR-ABL-transformed ES cells transplanted into irradiated mice induced a leukemic syndrome with many features of CML.171 If developed further, these models may well be able to retain the major advantage of cell linestheir ease of
manipulationwhile at the same time moving the in vitro system closer
to the clinical disease.
Bearing all these caveats in mind, there is no doubt that the study of
cell lines contributed significantly to our understanding of CML.
Particularly, many of the proteins that interact with Bcr-Abl were
identified in Ph-positive cell lines, where they are more abundantly
expressed than in primary cells. Thus, though these lines are
invaluable tools for screening, it is important to confirm the results
in primary cells.
Primary cells. The study of patient material and its comparison with normal hematopoietic progenitor cells is certainly the gold standard of CML research, particularly for the chronic phase of the disease. Much of the data refer to operationally defined cellular properties of CML versus normal cells, such as clonogenicity or adherence to bone marrow stroma; to give a comprehensive account of the cellular biology of CML would require a review in its own right. We will therefore focus on some areas in which the study of primary CML cells has been particularly instrumental to the study of the molecular biology of the disease. One of the main problems when studying primary cells is inherent in the very nature of chronic phase cellsthey tend to mature when
placed in culture. Thus, the window of time for in vitro studies is
narrow, and expansion of very primitive cells, the least prevalent but
most interesting population, is difficult and carries the risk for
introducing nonphysiologic alterations.172 Furthermore,
there is considerable variation between patients that frequently
results in an overlap rather than a clear distinction between normal
cells and CML cells. Last, results are unreliable unless clearly
defined cell populations such as CD34+ cells are studied.
To a large extent, these problems can be overcome by the introduction
of retroviral BCR-ABL expression vectors to murine or human
primary bone marrow cells (see "Animal models" below).
A striking example of how fruitful the comparison of primary cell
populations can be is the study of tyrosine-phosphorylated proteins in
CD34+ cells.112 This study led to the
subsequent identification of p62DOK74;173 and
SHIP2132 as mediators of Bcr-Abl-induced transformation. Moreover, it produced the important notion that Bcr-Abl tyrosine kinase
activity may have consequences similar to the activation of the KIT
receptor.112 Another example is the identification of CRKL
as the major tyrosine-phosphorylated protein in CML
neutrophils.73
The recent possibility of turning off the Bcr-Abl tyrosine kinase
activity in cell lines and primary cells with STI5717,8 provided the opportunity to study the effects of the BCR-ABL
gene when expressed from its natural BCR promoter at
"physiological" levels. This is certainly an advantage over
transduced cell systems; the drawback, however, is that effects related
to inhibition of the KIT and PDGFR kinases, and potentially other
unidentified tyrosine kinases, cannot be ruled out. Furthermore, the
Bcr-Abl protein, though kinase-inactive, is still present in the cells and may interfere with other proteins.
Animal models Thus far, no animals other than mice have been used for the study of CML in vivo. Various approaches have been taken.Engraftment of BCR-ABL-transformed cell lines in syngeneic mice. Murine factor-dependent cell lines such as 32D transduced with BCR-ABL give rise to an aggressive leukemia when transplanted into syngeneic recipients.60,174 This is an excellent in vivo model to test the efficacy of new drugs, such as the tyrosine kinase inhibitor STI571, in vivo. Furthermore, the impact on leukemogenicity of modifications within the Bcr-Abl protein and modifications to the respective cell lines (such as the introduction of co-stimulatory molecules174) can be tested. The main drawback is that the disease is a form of acute leukemia and is thus far from chronic phase CML. Engraftment of immunodeficient mice with human BCR-ABL-positive cells. Cell lines derived from human CML blast crisis are relatively easily propagated in severe combined immunodeficiency (SCID) mice.175 The distribution of the leukemia cells is fairly similar to the human disease, that is, they home to bone marrow and peripheral blood before they metastasize to nonhematopoietic tissues. More recently, it was shown that SCID mice can be engrafted with chronic phase CML cells if the cell inoculum is large enough (in the range of 1 × 108 cells).176 Up to 10% human cells were detectable in the recipient bone marrow and showed multilineage differentiation. Interestingly, most colonies were BCR-ABL negative and thus were derived from the patient's residual normal hematopoiesis. This is reminiscent of long-term bone marrow cultures of CML177 and shows that host factors modify the disease to a great extent, a problem that will persist, even if higher percentages of engraftment can eventually be achieved. A step into this direction is the use of nonobese diabetes-SCID mice. In addition to the SCID defect in V(D)J recombination, these animals lack functional natural killer cells. Chronic phase CML cells and, even more so, cells from accelerated phase or blast crisis readily engraft in these mice, and there is a significant correlation between engraftment and disease state.178 Interestingly, the cells were exclusively Ph-positive in most cases, in contrast to cells engrafted in SCID mice, as mentioned above. This may be attributed to technical reasons but may also reflect a genuine difference between the different strains of mice. We can anticipate that these murine models will be useful for studying certain aspects of CML, such as the response to novel forms of treatment. Their value in investigating the human disease will be limited because it is difficult to see how disease modification by host factors could ever be ruled out. Transgenic mouse models. Attempts to use BCR-ABL transgenic mice as a CML model go back to the late 1980s, when a full-length cDNA of BCR-ABL was not yet available and an artificial construct of human BCR sequences fused to v-abl was used instead.179 Since then, a number of studies have been published that clearly prove the oncogenic potential of BCR-ABL. Several different promoters were used to direct the expression to the desired target tissues. However, some problems were encountered. First, it became clear that Bcr-Abl has a toxic effect on embryogenesis,180 perhaps the consequence of a cytostatic effect in nonhematopoietic tissues.181 Recently, the expression of BCR-ABL from a tetracycline-repressible promoter effectively overcame this problem.182 Most striking, the leukemia in these transgenic mice is completely reversible on re-addition of tetracycline. The second problem with transgenic mice is that the P210 BCR-ABL variant relevant to CML is difficult to study because it is less efficient in inducing leukemia than P190, a finding that was again confirmed in a recent study.47 Third and most important, the types of leukemia that developed in these mice were acute and of either B- or T-lymphoid phenotype, regardless of whether they arose in P190 or P210 transgenic animals. Thus, they resembled BCR-ABL-positive ALL but not chronic-phase CML183,184. In fact, myeloid leukemias developed rarely, if at all. A recent report185 may represent a major advance in this respect. In this study, BCR-ABL was expressed from the Tec promoter, a cytoplasmic tyrosine kinase predominantly expressed in hematopoietic cells. Although the founder mice exhibited excessive proliferation of lymphoblasts, their progeny developed a CML-like disease, albeit after a relatively long latency period of approximately 10 months. Thus, it is likely that the problems of the transgenic models will eventually be resolved if the gene is targeted to the appropriate cell. Transduction of murine bone marrow cells with BCR-ABL retroviruses. In 1990, several groups reported that a CML-like myeloproliferative syndrome could be induced when P210BCR-ABL-infected marrow was transplanted into syngeneic recipients.6,186,187 Transplantation into secondary recipients frequently produced an identical disease while some mice developed acute leukemias of T- or B-cell phenotype, analogous to the development of lymphoid blast crisis in the clinical disease. Clonality was demonstrated in many cases. Roughly a quarter of the mice showed the myeloproliferative disease, whereas other recipients developed other distinct hematologic malignancies, such as macrophage tumors, B-ALL, T-ALL, and erythroleukemia. Most likely, these different diseases are the consequence of infection of different committed progenitor cells that, after transformation, give rise to the respective progeny. Not surprisingly, the infection conditions have a major impact on the disease phenotype.188 Building on the foundations of this early work, major improvements to the transduction-transplantation system have been made in the past few years. High-titer BCR-ABL retroviral stocks can be produced rapidly by transient transfection of packaging lines; the culture conditions have been refined, and the murine stem cell virus LTR has been introduced that allows for more efficient expression of BCR-ABL in the desired target cell. Combining all 3 improvements, 2 recent studies189,190 reported the induction of a transplantable CML-like disease in 100% of recipients. Pulmonary hemorrhage, a complication not found in human CML, was a frequent cause of death in both studies, demonstrating that these novel models, though a major step forward, may have their own distinct problems. Nevertheless, bone marrow transduction-transplantation most faithfully reproduces human CML, and further improvements are likely in the near future.
Clinically, chronic-phase CML does not represent a major
management problem because the elevated white blood cell count is readily controlled with cytotoxic agents in most patients, and neutrophil and platelet functions are largely normal. However, the
disease progresses inexorably to acceleration and blast crisis, often
within 5 years of diagnosis. The mechanisms underlying this evolution
remain enigmatic. Deletion or inactivation of p16,191 p53,192 and the retinoblastoma gene
product193 have been reported but occur relatively rarely
and, similar to the overexpression of EVI-1,194
are not specific for blast crisis CML. This probably indicates that a
wide variety of lesions, possibly multiple "cooperating" lesions,
are required to induce the phenotype of blast crisis. Perhaps even more
intriguing is why the cells acquire these additional lesions in the
first place. A recent report shows that Bcr-Abl enhances the
mutation rate in the Na-K-ATPase and in the HPRT genomic loci, both
commonly used markers to measure mutation frequency. Along with this
goes enhanced expression of DNA polymerase
Attempts at designing therapeutic tools for CML based on our
current knowledge of the molecular and cell biology of the disease have
concentrated on 3 main areas Perhaps the most exciting of the molecularly designed therapeutic
approaches was brought about by the advent of signal transduction inhibitors (STI), which block or prevent a protein from exerting its
role in the oncogenic pathway. Because the main transforming property
of the Bcr-Abl protein is effected through its constitutive tyrosine
kinase activity, direct inhibition of such activity seems to be the
most logical means of silencing the oncoprotein. To this effect,
several tyrosine kinase inhibitors have been evaluated for their
potential to modify the phenotype of CML cells. The first to be tested
were compounds isolated from natural sources, such as the iso-flavonoid
genistein and the antibiotic herbimycin A.204 Later,
synthetic compounds were developed through a rational design of
chemical structures capable of competing with the adenosine triphosphate (ATP) or the protein substrate for the binding site in the
catalytic center of the kinase205 (Figure
7).
The most promising of these compounds is the 2-phenylaminopyrimidine
STI571 (formerly CGP57418B; Novartis Pharmaceutics, Basel, Switzerland), which specifically inhibits Abl tyrosine kinase at
micromolar concentrations.206 Inhibition of the Bcr-Abl
kinase activity by this compound results in the transcriptional
modulation of various genes involved in the control of the cell cycle,
cell adhesion, and cytoskeleton organization, leading the Ph-positive cell to an apoptotic death.86 Furthermore, STI571
selectively suppresses the growth of CML primary cells and cell lines
in vitro7,8 and in mice.7,207 Its remarkable
specificity and efficacy led to consideration of the drug for
therapeutic use. Thus, in the spring of 1998, a phase 1 clinical trial
was initiated in the United States in which patients with CML in
chronic phase resistant to IFN- An alternative or a supplement to direct inhibition of Bcr-Abl is interference with proteins that are critical for Bcr-Abl-induced transformation (Figure 4). One of these proteins is Grb2, whose SH2 domain binds directly to Bcr-Abl through the phosphorylated tyrosine 177 within the Bcr portion of the chimera57 and is essential for activation of the Ras pathway (Figure 6).209 Another good candidate is Ras itself, whose activity depends on its attachment to the cell membrane through a prenyl (usually a farnesyl) group. Thus, farnesyl transferase inhibitors (FTI) have been studied for their effect in inhibiting the proliferation of ALL210 and juvenile myelomonocytic leukemia cells,211 and they may be useful for the control of CML cells. Additional targets worth considering are represented by PI-3 and Src kinases, of which the available inhibitors have been shown to suppress colony formation of primary progenitors,127 proliferation of BCR-ABL-transfected cell lines, or both.212,213 It is envisaged that the progressive unraveling of which pathways are really essential for the development of the disease, coupled to rapid advances in biotechnology, will bring us the ideal combination of rationally designed drugs that can tip the balance toward the re-establishment of normal hematopoiesis in CML.
Though this be madness, yet there is method in it. (Shakespeare W., Hamlet. Act 2, scene 2.) There are 2 ways to conclude this review after going through the vast amount of data presented. Surely one could argue that despite all these data, there is still no clear picture emerging and each piece of additional information adds only more confusion. Alternatively, what might help us against capitulation in the face of complexity is to try to simplify without oversimplification. Can we build a model of CML that incorporates all the scientific data available but still retains clarity? In other words, could we explain how Bcr-Abl works in a few sentences to somebody who has never heard of it? Perhaps the most promising approach might be to try to link the biologic behavior of a CML cell to the underlying molecular events (Figure 5). Crucially, we should be able to picture this scenario relying on BCR-ABL alone because, at least until now, there is no unequivocal evidence that additional genetic lesions are present during chronic phase. We do not know how long it takes to move from the initial genetic event to fully established chronic-phase CML, but there is good reason to believe that the proliferative advantage of CML over normal cells is limited. Together with the largely normal differentiation capacity and function of CML blood cells, one feels that Ph-positive hematopoiesis cannot be so much different from normal hematopoiesis until the disease accelerates. Thus, Bcr-Abl is likely to hijack pathways that normally increase blood cell output in response to physiologic stimuli rather than to interrupt or replace them with pathways that are not normally used in hematopoietic cells. Indeed, there is plenty of experimental evidence to support this notion. Importantly, Bcr-Abl is capable of activating survival pathways along with proliferative stimuli without the need for a second cooperating genetic lesion; in this way, the apoptotic response that would otherwise follow an isolated proliferative stimulus is avoided. The sustained dependence on growth factors is an indication that Bcr-Abl is not a complete substitute; rather, it tips the balance to provide a limited growth advantage in vivo. This growth advantage is also dependent on specific survival conditions: transient regeneration of Ph-negative hematopoiesis is often observed after autografting, even when the autograft seems to be comprised exclusively of Ph-positive stem cells, and long-term cultures initiated from patients with chronic-phase CML become dominated by BCR-ABL-negative cells after some time.177 Thus, there appears to be a specific interaction (or noninteraction) of CML progenitor cells with their microenvironment that is crucial to maintain their proliferative advantage. Whether this interaction is stimulatory for CML over normal progenitor cells or inhibitory for normal over CML progenitor cells remains to be seen. Similarly, we can look at extramedullary hematopoiesis as a loss of function (ie, loss of the capacity to respond to negative signals) or a gain of function (ie, acquisition of a capacity to respond to positive signals that are not provided in the bone marrow) phenomenon. Much of the evidence implicates integrins in mediating these abnormal interactions, but other proteins may also play a role. Overall, it appears that the organization of cell membrane and cytoskeleton is more profoundly perturbed in CML progenitor cells than might be anticipated from the largely normal function of their progeny. Furthermore, Bcr-Abl may interfere with the "wiring" between integrin receptors on the cell surface and the nucleus and so disturb the communication of the cell with its environment. Another mechanism may also be important: Bcr-Abl appears to induce the degradation of certain inhibitory proteins. This might thwart cellular counter-reactions that would otherwise be activated, rather like cutting the telephone cable before the police can be called in. Many questions remain unanswered. Why is there a predominantly myeloid expansion when all 3 lineages carry the translocation? What is the biologic basis for the extraordinary variability in the clinical course of a disease that appears to carry just a single genetic lesion? What is the molecular basis for the genomic instability that we see clinically as relentless progression to blast crisis? Where do we go from here? The more we learn about the pathogenesis of CML, the more we realize its extraordinary complexity. Perhaps one should not be too surprised because it has become clear that cellular processes tend to rely on integrated networks rather than on straight unidirectional pathways. Only in this way can the cell achieve the flexibility required to respond to the various stimuli within a multicellular organism. Clearly, some components must be more important, and some less so, in the transformation network operated by Bcr-Abl. Absolutely essential features may be restricted to functional domains and to certain residues of the Bcr-Abl protein itself, and downstream effectors may be able to substitute for each other, at least to some extent. In this respect, the use of knockout mice that lack specific downstream molecules will allow one to define their precise relevance for Bcr-Abl-mediated cellular transformation. It may turn out that the combined elimination of several components abrogates transformation by Bcr-Abl, whereas each component individually is of limited significance. Chronic phase CML operates very much by exploiting physiologic pathways, perhaps by gently "coaxing" hematopoiesis toward the classical CML phenotype; nevertheless it prepares the ground for blast crisis. Thus, to understand CML, we must study its chronic phase. We must move away from artificial systems, such as transduced fibroblasts, and take on the demanding task of studying signal transduction in primary progenitor cells.
Submitted November 16, 1999; accepted July 12, 2000.
Supported by grants from Leukaemia Research Fund (UK) and the Dr Ernst und Anita Bauer Stiftung (Germany).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Michael W. N. Deininger, Department of Hematology/Oncology, University of Leipzig, Johannisallee 32, Leipzig 04103, Germany; e-mail: deim{at}medizin.uni-leipzig.de.
1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497. 2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]. Nature. 1973;243:290-293[Medline] [Order article via Infotrieve]. 3. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280[Medline] [Order article via Infotrieve]. 4. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99[Medline] [Order article via Infotrieve].
5.
Lugo TG, Pendergast AM, Muller AJ, Witte ON.
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Science.
1990;247:1079-1082
6.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830 7. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566[Medline] [Order article via Infotrieve].
8.
Deininger M, Goldman JM, Lydon NB, Melo JV.
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells.
Blood.
1997;90:3691-3698
9.
Druker BJ, Talpaz M, Resta D, et al.
Clinical efficacy and safety of an ABL-specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia [abstract].
Blood.
1999;94:368
10.
Abelson HT, Rabstein LS.
Lymphosarcoma: virus-induced thymic-independent disease in mice.
Cancer Res.
1970;30:2213-2222 11. Laneuville P. Abl tyrosine protein kinase. Semin Immunol. 1995;7:255-266[Medline] [Order article via Infotrieve]. 12. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell. 1995;80:237-248[Medline] [Order article via Infotrieve]. 13. Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994;13:2341-2351[Medline] [Order article via Infotrieve]. 14. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell. 1989;58:669-678[Medline] [Order article via Infotrieve].
15.
Kipreos ET, Wang JY.
Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA.
Science.
1992;256:382-385 16. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 1993;12:1533-1546[Medline] [Order article via Infotrieve].
17.
Kipreos ET, Wang JY.
Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity.
Science.
1990;248:217-220 18. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell. 1994;77:121-131[Medline] [Order article via Infotrieve]. 19. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399:814-817[Medline] [Order article via Infotrieve].
20.
Lewis JM, Schwartz MA.
Integrins regulate the association and phosphorylation of paxillin by c-Abl.
J Biol Chem.
1998;273:14225-14230 21. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999;9:179-186[Medline] [Order article via Infotrieve]. 22. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991;65:1153-1163[Medline] [Order article via Infotrieve]. 23. Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell. 1991;65:1165-1175[Medline] [Order article via Infotrieve].
24.
Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM.
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
Science.
1994;266:129-133
25.
McWhirter JR, Galasso DL, Wang JY.
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
Mol Cell Biol.
1993;13:7587-7595 26. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J. 1996;318:729-747.
27.
Montaner S, Perona R, Saniger L, Lacal JC.
Multiple signaling pathways lead to the activation of the nuclear factor 28. Diekmann D, Brill S, Garrett MD, et al. Bcr encodes a GTPase-activating protein for p21rac. Nature. 1991;351:400-402[Medline] [Order article via Infotrieve]. 29. Diekmann D, Nobes CD, Burbelo PD, Abo A, Hall A. Rac GTPase interacts with GAPs and target proteins through multiple effector sites. EMBO J. 1995;14:5297-5305[Medline] [Order article via Infotrieve]. 30. Wu Y, Liu J, Arlinghaus RB. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene. 1998;16:141-146[Medline] [Order article via Infotrieve]. 31. Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene. 1997;14:2367-2372[Medline] [Order article via Infotrieve]. 32. Liu J, Wu Y, Ma GZ, et al. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol. 1996;16:998-1005[Abstract]. 33. Voncken JW, van Schaick H, Kaartinen V, et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell. 1995;80:719-728[Medline] [Order article via Infotrieve]. 34. Voncken JW, Kaartinen V, Groffen J, Heisterkamp N. Bcr/Abl associated leukemogenesis in bcr null mutant mice. Oncogene. 1998;16:2029-2032[Medline] [Order article via Infotrieve].
35.
Melo JV.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Blood.
1996;88:2375-2384 36. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia? Leukemia. 1994;8:208-211[Medline] [Order article via Infotrieve]. 37. Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol. 1999;107:581-586[Medline] [Order article via Infotrieve].
38.
Pane F, Frigeri F, Sindona M, et al.
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction).
Blood.
1996;88:2410-2414
39.
Wilson G, Frost L, Goodeve A, Vandenberghe E, Peake I, Reilly J.
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
Blood.
1997;89:3064
40.
van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC.
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood.
1996;87:5213-5217 41. Melo JV. BCR-ABL gene variants. Baillieres.Clin.Haematol. 1997;10:203-222[Medline] [Order article via Infotrieve]. 42. Leibundgut EO, Jotterand M, Rigamonti V, et al. A novel BCR-ABL transcript e2a2 in a chronic myelogenous leukaemia patient with a duplicated Ph-chromosome and monosomy 7. Br J Haematol. 1999;106:1041-1044[Medline] [Order article via Infotrieve]. 43. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996;16:4107-4116[Abstract].
44.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM.
The novel activation of ABL by fusion to an ets-related gene, TEL.
Cancer Res.
1995;55:34-38
45.
Cazzaniga G, Tosi S, Aloisi A, et al.
The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.
Blood.
1999;94:4370-4373
46.
Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA.
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
J Exp Med.
1999;189:1399-1412
47.
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM.
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Blood.
2000;95:2913-2921 48. Tanaka K, Takechi M, Hong J, et al. 9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors. J Radiat Res. 1989;30:352-358.
49.
Corso A, Lazzarino M, Morra E, et al.
Chronic myelogenous leukemia and exposure to ionizing radiation
50.
Deininger MW, Bose S, Gora-Tybor J, Yan XH, Goldman JM, Melo JV.
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.
Cancer Res.
1998;58:421-425
51.
Kozubek S, Lukasova E, Ryznar L, et al.
Distribution of ABL and BCR genes in cell nuclei of normal and irradiated lymphocytes.
Blood.
1997;89:4537-4545
52.
Neves H, Ramos C, da Silva MG, Parreira A, Parreira L.
The nuclear topography of ABL, BCR, PML, and RAR
53.
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV.
The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease.
Blood.
1998;92:3362-3367 54. Biernaux C, Sels A, Huez G, Stryckmans P. Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant. 1996;17(suppl 3):S45-S47.
55.
Posthuma EF, Falkenburg JH, Apperley JF, et al.
HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia: the Chronic Leukemia Working Party of the EBMT.
Blood.
1999;93:3863-3865
56.
Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA.
Evidence for a multistep pathogenesis of chronic myelogenous leukemia.
Blood.
1981;58:158-163 57. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185[Medline] [Order article via Infotrieve]. 58. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161-171[Medline] [Order article via Infotrieve].
59.
Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL.
Differential complementation of Bcr-Abl point mutants with c-Myc.
Science.
1994;264:424-426
60.
Ilaria RL Jr, Van Etten RA.
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Blood.
1995;86:3897-3904
61.
Mayer BJ, Baltimore D.
Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.
Mol Cell Biol.
1994;14:2883-2894
62.
Danial NN, Pernis A, Rothman PB.
Jak-STAT signaling induced by the v-abl oncogene.
Science.
1995;269:1875-1877
63.
Shi Y, Alin K, Goff SP.
Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.
Genes Dev.
1995;9:2583-2597
64.
Dai Z, Pendergast AM.
Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.
Genes Dev.
1995;9:2569-2582
65.
Cicchetti P, Mayer BJ, Thiel G, Baltimore D.
Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho.
Science.
1992;257:803-806
66.
Dai Z, Quackenbush RC, Courtney KD, et al.
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway.
Genes Dev.
1998;12:1415-1424
67.
Wen ST, Van ER.
The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity.
Genes Dev.
1997;11:2456-2467
68.
Goga A, McLaughlin J, Pendergast AM, et al.
Oncogenic activation of c-ABL by mutation within its last exon.
Mol Cell Biol.
1993;13:4967-4975 69. Jackson PK, Paskind M, Baltimore D. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene. 1993;8:1943-1956[Medline] [Order article via Infotrieve]. 70. Janssen JW, Ridge SA, Papadopoulos P, et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol. 1995;90:222-224[Medline] [Order article via Infotrieve].
71.
Reiter A, Sohal J, Kulkarni S, et al.
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the 1(8;13)(p11;q12) myeloproliferative syndrome.
Blood.
1998;92:1735-1742 72. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316[Medline] [Order article via Infotrieve].
73.
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ.
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
J Biol Chem.
1994;269:22925-22928 74. Carpino N, Wisniewski D, Strife A, et al. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell. 1997;88:197-204[Medline] [Order article via Infotrieve].
75.
Matsuguchi T, Salgia R, Hallek M, et al.
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
J Biol Chem.
1994;269:5016-5021 76. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995;11:1149-1155[Medline] [Order article via Infotrieve].
77.
Salgia R, Li JL, Lo SH, et al.
Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL.
J Biol Chem.
1995;270:5039-5047 78. Gotoh A, Miyazawa K, Ohyashiki K, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol. 1995;23:1153-1159[Medline] [Order article via Infotrieve].
79.
Ernst TJ, Slattery KE, Griffin JD.
p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes.
J Biol Chem.
1994;269:5764-5769 80. Gotoh A, Miyazawa K, Ohyashiki K, Toyama K. Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph-positive ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. Leukemia. 1994;8:115-120[Medline] [Order article via Infotrieve]. 81. Andoniou CE, Thien CB, Langdon WY. Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBO J. 1994;13:4515-4523[Medline] [Order article via Infotrieve]. 82. Matsuguchi T, Inhorn RC, Carlesso N, Xu G, Druker B, Griffin JD. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 1995;14:257-265[Medline] [Order article via Infotrieve].
83.
Tauchi T, Feng GS, Shen R, et al.
SH2-containing phosphotyrosine phosphatase Syp is a target of p210 bcr-abl tyrosine kinase.
J Biol Chem.
1994;269:15381-15387
84.
LaMontagne KR Jr, Flint AJ, Franza BR Jr, Pandergast AM, Tonks NK.
Protein tyrosine phosphatase 1B antagonizes signaling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
Mol Cell Biol.
1998;18:2965-2975
85.
LaMontagne KR Jr, Hannon G, Tonks NK.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Proc Natl Acad Sci U S A.
1998;95:14094-14099
86.
Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV.
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer Res.
2000;60:2049-2055 87. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature. 1987;328:342-344[Medline] [Order article via Infotrieve]. 88. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773[Medline] [Order article via Infotrieve].
89.
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ.
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.
Blood.
1994;83:2038-2044 90. Verfaillie CM, Hurley R, Lundell BI, Zhao C, Bhatia R. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol. 1997;97:40-52[Medline] [Order article via Infotrieve]. 91. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 1994;94:384-391.
92.
Zhao RC, Tarone G, Verfaillie CM.
Presence of the adhesion inhibitory
93.
Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY.
Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport.
Proc Natl Acad Sci U S A.
1996;93:15174-15179
94.
Uemura N, Griffin JD.
The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration.
J Biol Chem.
1999;274:37525-37532 95. Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996;12:839-846[Medline] [Order article via Infotrieve].
96.
Salgia R, Pisick E, Sattler M, et al.
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
J Biol Chem.
1996;271:25198-25203
97.
Sattler M, Salgia R, Shrikhande G, et al.
Differential signaling after 98. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996;98:521-528[Medline] [Order article via Infotrieve]. 99. Pelicci G, Lanfrancone L, Salcini AE, et al. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 1995;11:899-907[Medline] [Order article via Infotrieve].
100.
Senechal K, Halpern J, Sawyers CL.
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
J Biol Chem.
1996;271:23255-23261
101.
Heaney C, Kolibaba K, Bhat A, et al.
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Blood.
1997;89:297-306
102.
Watzinger F, Gaiger A, Karlic H, Becher R, Pillwein K, Lion T.
Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia.
Cancer Res.
1994;54:3934-3938 103. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14:3136-3145[Medline] [Order article via Infotrieve]. 104. Cahill MA, Janknecht R, Nordheim A. Signalling pathways: jack of all cascades. Curr Biol. 1996;6:16-19[Medline] [Order article via Infotrieve]. 105. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 1994;13:5887-5895[Medline] [Order article via Infotrieve]. 106. Cortez D, Reuther GW, Pendergast AM. The BCR-ABL tyrosine kinase activates mitotic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342[Medline] [Order article via Infotrieve].
107.
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL.
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Proc Natl Acad Sci U S A.
1995;92:11746-11750
108.
Skorski T, Wlodarski P, Daheron L, et al.
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.
Proc Natl Acad Sci U S A.
1998;95:11858-11862
109.
Shi C-S, Tuscano JM, Witte O, Kehrl JH.
GCKR links the BCR-ABL oncogene and RAS to the stress-activated protein kinase pathway.
Blood.
1999;93:1338-1345
110.
Wilson Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB.
P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
Cancer Res.
1996;56:3426-3430 111. Hallek M, Danhauser Riedl S, Herbst R, et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996;94:5-16[Medline] [Order article via Infotrieve]. 112. Wisniewski D, Strife A, Berman E, Clarkson B. c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia. 1996;10:229-237[Medline] [Order article via Infotrieve].
113.
Di Cristofano A, Carpino N, Dunant N, et al.
Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins.
J Biol Chem.
1998;273:4827-4830
114.
Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ.
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
J Biol Chem.
1998;273:32360-32368
115.
Ilaria RL Jr, Van Etten RA.
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
J Biol Chem.
1996;271:31704-31710 116. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720-4728[Abstract].
117.
de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L.
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Blood.
1999;94:1108-1112 118. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754-4765[Medline] [Order article via Infotrieve].
119.
Horita M, Andreu EJ, Benito A, et al.
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
J Exp Med.
2000;191:977-984
120.
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD.
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.
Blood.
2000;95:2118-2125
121.
Daley GQ, Baltimore D.
Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
Proc Natl Acad Sci U S A.
1988;85:9312-9316
122.
Sirard C, Laneuville P, Dick JE.
Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism.
Blood.
1994;83:1575-1585
123.
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C.
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.
Proc Natl Acad Sci U S A.
1999;96:12804-12809 124. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol. 1995;91:387-393[Medline] [Order article via Infotrieve]. 125. Jonuleit T, Peschel C, Schwab R, et al. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol. 1998;100:295-303[Medline] [Order article via Infotrieve]. 126. Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM, Whetton AD. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene. 1998;17:667-672[Medline] [Order article via Infotrieve].
127.
Skorski T, Kanakaraj P, Nieborowska Skorska M, et al.
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Blood.
1995;86:726-736 128. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161[Medline] [Order article via Infotrieve]. 129. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435-437[Medline] [Order article via Infotrieve].
130.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G.
Interleukin-3-induced phosphorylation of bad through the protein kinase akt.
Science.
1998;278:687-689
131.
Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold A, Rohrschneider LR.
p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity.
Genes Dev.
1996;10:1084-1095
132.
Wisniewski D, Strife A, Swendeman S, et al.
A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
Blood.
1999;93:2707-2720 133. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910[Medline] [Order article via Infotrieve].
134.
Zou X, Rudchenko S, Wong K, Calame K.
Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases.
Genes Dev.
1997;11:654-662 135. Stewart MJ, Litz Jackson S, Burgess GS, Williamson EA, Leibowitz DS, Boswell HS. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation: studies in murine myeloid cells. Leukemia. 1995;9:1499-1507[Medline] [Order article via Infotrieve]. 136. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 1992;359:552-554[Medline] [Order article via Infotrieve]. 137. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119-128[Medline] [Order article via Infotrieve]. 138. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1992;85:9312-9316. 139. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541[Abstract].
140.
Bedi A, Barber JP, Bedi GC, et al.
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Blood.
1995;86:1148-1158
141.
Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E.
BCR-ABL delays apoptosis upstream of procaspase-3 activation.
Blood.
1998;91:2415-2422
142.
Amarante Mendes GP, Naekyung Kim C, Liu L, et al.
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Blood.
1998;91:1700-1705 143. Sanchez Garcia I, Martin Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol. 1997;267:225-228[Medline] [Order article via Infotrieve]. 144. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87:629-638[Medline] [Order article via Infotrieve]. 145. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87:619-628[Medline] [Order article via Infotrieve].
146.
Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL.
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.
Mol Cell Biol.
2000;20:1179-1186
147.
Majewski M, Nieborowska-Skorska M, Salomoni P, et al.
Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt.
Cancer Res.
1999;59:2815-2819
148.
Gabriele L, Phung J, Fukumoto J, et al.
Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein.
J Exp Med.
1999;190:411-421
149.
Hao SX, Ren R.
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Mol Cell Biol.
2000;20:1149-1161 150. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317[Medline] [Order article via Infotrieve].
151.
Scheller M, Foerster J, Heyworth CM, et al.
Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein.
Blood.
1999;94:3764-3771 152. Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol. 1995;7:825-834[Medline] [Order article via Infotrieve]. 153. Santucci MA, Anklesaria P, Laneuville P, et al. Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity. Int J Radiat Oncol Biol Phys. 1993;26:831-836[Medline] [Order article via Infotrieve]. 154. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol. 1996;95:501-507[Medline] [Order article via Infotrieve].
155.
McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR.
Regulation of the Fas apoptotic cell death pathway by Abl.
J Biol Chem.
1995;270:22625-22631
156.
Selleri C, Maciejewski J, Pane F, et al.
Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Blood.
1998;92:981-989 157. Gora-Tybor J, Deininger M, Goldman JM, Melo JV. The susceptibility of Philadelpha chromosome-positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol. 1998;103:716-720[Medline] [Order article via Infotrieve]. 158. Maguer Satta V, Burl S, Liu L, et al. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene. 1997;16:237-248.
159.
Roger R, Issaad C, Pallardy M, et al.
BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Blood.
1996;87:1113-1122 160. Tordaro GJ, Green H. An assay for cellular transformation by SV40. Virology. 1964;23:117-119[Medline] [Order article via Infotrieve].
161.
Lugo TG, Witte ON.
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
Mol Cell Biol.
1989;9:1263-1270
162.
Daley GQ, McLaughlin J, Witte ON, Baltimore D.
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
Science.
1987;237:532-535 163. Renshaw MW, Kipreos ET, Albrecht MR, Wang JY. Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. EMBO J. 1992;11:3941-3951[Medline] [Order article via Infotrieve]. 164. Drexler HG, MacLeod RA, Uphoff CC. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res. 1999;23:207-215[Medline] [Order article via Infotrieve]. 165. Spencer A, Yan XH, Chase A, Goldman JM, Melo JV. BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions. Br J Haematol. 1996;94:654-658[Medline] [Order article via Infotrieve].
166.
Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG.
The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
Proc Natl Acad Sci U S A.
1996;93:14845-14850
167.
Klucher KM, Lopez DV, Daley GQ.
Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.
Blood.
1998;91:3927-3934 168. Ghaffari S, Daley GQ, Lodish HF. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia. 1999;13:1200-1206[Medline] [Order article via Infotrieve].
169.
Era T, Witte ON.
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Proc Natl Acad Sci U S A.
2000;97:1737-1742 170. Turhan AG, Bonnet ML, Le Pesteur D, Mitjavila M, Vainschenker W, Sainteny F. Generation of an embryonic stem cell (ES) model of chronic myelogenous leukemia (CML) [abstract]. Blood. 1999;94:101a. 171. Peters DG, Perlingeiro RC, Klucher KM, et al. Generation of a hematopoietic stem cell line from ES cells using the oncogene BCR/ABL [abstract]. Blood. 1999;94:252a. 172. Garin MI, Apperley JF, Melo JV. Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrow and mobilised peripheral blood. Eur J Haematol. 2000;64:85-92[Medline] [Order article via Infotrieve].
173.
Kashige N, Carpino N, Kobayashi R.
Tyrosine phosphorylation of p62dok by p210bcr-abl inhibits RasGAP activity.
Proc Natl Acad Sci U S A.
2000;97:2093-2098
174.
Matulonis UA, Dosiou C, Lamont C, et al.
Role of B7-1 in mediating an immune response to myeloid leukemia cells.
Blood.
1995;85:2507-2515
175.
Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON.
Propagation of human blastic myeloid leukemias in the SCID mouse.
Blood.
1992;79:2089-2098
176.
Sirard C, Lapidot T, Vormoor J, et al.
Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.
Blood.
1996;87:1539-1548 177. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med. 1983;308:1493-1498[Abstract].
178.
Dazzi F, Capelli D, Hasserjian R, et al.
The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Blood.
1998;92:1390-1396
179.
Hariharan IK, Harris AW, Crawford M, et al.
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
Mol Cell Biol.
1989;9:2798-2805 180. Heisterkamp N, Jenster G, Kioussis D, Pattengale PK, Groffen J. Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Res. 1991;1:45-53[Medline] [Order article via Infotrieve]. 181. Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 1996;15:1583-1595[Medline] [Order article via Infotrieve]. 182. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24:57-60[Medline] [Order article via Infotrieve]. 183. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;344:251-253[Medline] [Order article via Infotrieve].
184.
Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N.
BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Blood.
1995;86:4603-4611
185.
Honda H, Oda H, Suzuki T, et al.
Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210 bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Blood.
1998;91:2067-2075 186. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078[Medline] [Order article via Infotrieve].
187.
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N.
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci U S A.
1990;87:6649-6653
188.
Elefanty AG, Cory S.
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Mol Cell Biol.
1992;12:1755-1763
189.
Pear WS, Miller JP, Xu L, et al.
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Blood.
1998;92:3780-3792
190.
Zhang X, Ren R.
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Blood.
1998;92:3829-3840
191.
Sill H, Goldman JM, Cross NC.
Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.
Blood.
1995;85:2013-2016
192.
Feinstein E, Cimino G, Gale RP, et al.
p53 in chronic myelogenous leukemia in acute phase.
Proc Natl Acad Sci U S A.
1991;88:6293-6297
193.
Towatari M, Adachi K, Kato H, Saito H.
Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.
Blood.
1991;78:2178-2181 194. Ogawa S, Mitani K, Kurokawa M, et al. Abnormal expression of Evi-1 gene in human leukemias. Hum Cell. 1996;9:323-332[Medline] [Order article via Infotrieve]. 195. Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18:2676-2680[Medline] [Order article via Infotrieve].
196.
Takedam N, Shibuya M, Maru Y.
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Proc Natl Acad Sci U S A.
1999;96:203-207
197.
Honda H, Ushijima T, Wakazono K, et al.
Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Blood.
2000;95:1144-1150 198. O'Brien SG, Smetsers TF. BCR-ABL as a target for antisense intervention. In: Stein CA,Krieg AM, eds. Applied antisense oligonucleotide technology. New York: Wiley-Liss; 1997:207-230.
199.
Gewirtz AM, Sokol DL, Ratajczak MZ.
Nucleic acid therapeutics: state of the art and future prospects.
Blood.
1998;92:712-736
200.
James HA, Gibson I.
The therapeutic potential of ribozymes.
Blood.
1998;91:371-382
201.
Cobaleda C, Sanchez-Garcia I.
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
Blood.
2000;95:731-737 202. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27:1477-1486[Medline] [Order article via Infotrieve].
203.
Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al.
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Blood.
2000;95:1781-1787 204. Boutin JA. Tyrosine protein kinase inhibition and cancer. Int J Biochem. 1994;26:1203-1226[Medline] [Order article via Infotrieve].
205.
Levitzki A, Gazit A.
Tyrosine kinase inhibition: an approach to drug development.
Science.
1995;267:1782-1788
206.
Buchdunger E, Zimmermann J, Mett H, et al.
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Proc Natl Acad Sci U S A.
1995;92:2558-2562
207.
LeCoutre P, Mologni L, Cleris L, et al.
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
J Natl Cancer Inst.
1999;91:163-168
208.
Mahon FX, Deininger MW, Schultheis B, et al.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood.
2000;96:1070-1079
209.
Gishizky ML, Cortez D, Pendergast AM.
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Proc Natl Acad Sci U S A.
1995;92:10889-10893 210. Perrey DA, Scannell MP, Narla RK, Navara C, Uckun FM. RAS endoprotease inhibitors are potent cytotoxic agents against acute lymphoblastic leukemia. Blood [abstract]. 1998;92:599.
211.
Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP.
Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyl transferase inhibitors.
Blood.
2000;95:639-645 212. Gaston I, Stenberg PE, Bhat A, Druker BJ. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells. Exp Hematol. 2000;28:77-86[Medline] [Order article via Infotrieve].
213.
Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M.
The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.
J Biol Chem.
1997;272:33260-33270
214.
Druker B, Okuda K, Matulonis U, Salgia R, Roberts T, Griffin JD.
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
Blood.
1992;79:2215-2220
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. H. Kim, W. Xu, S. Kamel-Reid, X. Liu, C. W. Jung, S. Kim, and J. H. Lipton Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy Ann. Onc., October 29, 2009; (2009) mdp452v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Oehler, K. Y. Yeung, Y. E. Choi, R. E. Bumgarner, A. E. Raftery, and J. P. Radich The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data Blood, October 8, 2009; 114(15): 3292 - 3298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Lucas, R. J. Harris, A. Giannoudis, A. Davies, K. Knight, S. J. Watmough, L. Wang, and R. E. Clark Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript Haematologica, October 1, 2009; 94(10): 1362 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-P. Gratacap, V. Martin, M.-C. Valera, S. Allart, C. Garcia, P. Sie, C. Recher, and B. Payrastre The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo Blood, August 27, 2009; 114(9): 1884 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Jagani, K. Song, J. L. Kutok, M. R. Dewar, A. Melet, T. Santos, A. Grassian, S. Ghaffari, C. Wu, R. Ren, et al. Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL-Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors Cancer Res., August 15, 2009; 69(16): 6546 - 6555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grosso, A. Puissant, M. Dufies, P. Colosetti, A. Jacquel, K. Lebrigand, P. Barbry, M. Deckert, J. P. Cassuto, B. Mari, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors Mol. Cancer Ther., July 1, 2009; 8(7): 1924 - 1933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miyazaki, N. Yamasaki, H. Oda, T. Kuwata, Y. Kanno, M. Miyazaki, Y. Komeno, J. Kitaura, Z.-i. Honda, S. Warming, et al. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia Blood, May 7, 2009; 113(19): 4702 - 4710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tyler Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia Ann. Pharmacother., May 1, 2009; 43(5): 920 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wodarz Use of oncolytic viruses for the eradication of drug-resistant cancer cells J R Soc Interface, February 6, 2009; 6(31): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood, December 15, 2008; 112(13): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Agirre, A. Jimenez-Velasco, E. San Jose-Eneriz, L. Garate, E. Bandres, L. Cordeu, O. Aparicio, B. Saez, G. Navarro, A. Vilas-Zornoza, et al. Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth Mol. Cancer Res., December 1, 2008; 6(12): 1830 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Lee, W. Ma, X. Zhang, F. Giles, J. Cortes, H. Kantarjian, and M. Albitar BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations Mol. Cancer Ther., December 1, 2008; 7(12): 3834 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, W. Fu, S. Prabhu, J. C. Moore, J. Ko, J. W. Kim, B. J. Druker, V. Trapp, J. Fruehauf, H. Gram, et al. Inhibition of Polysome Assembly Enhances Imatinib Activity against Chronic Myelogenous Leukemia and Overcomes Imatinib Resistance Mol. Cell. Biol., October 15, 2008; 28(20): 6496 - 6509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood, September 1, 2008; 112(5): 1960 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kavalerchik, D. Goff, and C. H.M. Jamieson Chronic Myeloid Leukemia Stem Cells J. Clin. Oncol., June 10, 2008; 26(17): 2911 - 2915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Puissant, S. Grosso, A. Jacquel, N. Belhacene, P. Colosetti, J.-P. Cassuto, and P. Auberger Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol FASEB J, June 1, 2008; 22(6): 1894 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La Rosee, S. Holm-Eriksen, H. Konig, N. Hartel, T. Ernst, J. Debatin, M. C. Mueller, P. Erben, A. Binckebanck, L. Wunderle, et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib Haematologica, May 1, 2008; 93(5): 765 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weisberg, L. Banerji, R. D. Wright, R. Barrett, A. Ray, D. Moreno, L. Catley, J. Jiang, E. Hall-Meyers, M. Sauveur-Michel, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells Blood, April 1, 2008; 111(7): 3723 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fojo Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better Oncologist, March 1, 2008; 13(3): 277 - 283. [Full Text] [PDF]
|
|
|
|
|
|
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood, March 1, 2008; 111(5): 2843 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Huguet, N. Giocanti, C. Hennequin, M. Croisy, E. Touboul, and V. Favaudon Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells Mol. Cancer Ther., February 1, 2008; 7(2): 398 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Duncan, C. A. Goetz, S. J. Stein, K. J. Mayo, B. J. Skaggs, K. Ziegelbauer, C. L. Sawyers, and A. S. Baldwin I{kappa}B kinase {beta} inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells Mol. Cancer Ther., February 1, 2008; 7(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Jamieson Chronic Myeloid Leukemia Stem Cells Hematology, January 1, 2008; 2008(1): 436 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McLaughlin, D. Cheng, O. Singer, R. U. Lukacs, C. G. Radu, I. M. Verma, and O. N. Witte Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics PNAS, December 18, 2007; 104(51): 20501 - 20506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dorshkind and O. N. Witte Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL Genes & Dev., September 15, 2007; 21(18): 2249 - 2252. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lee, J. H. Bae, M. J. Kim, H. S. Lee, M. K. Lee, B. S. Chung, D. W. Kim, C. D. Kang, and S. H. Kim Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1084 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J. Peralta, J. Wang, G. J. Tsongalis, D. Belloni, D. Chan, J. R. Eshleman, et al. Development of an Integrated Assay for Detection of BCR-ABL RNA Clin. Chem., September 1, 2007; 53(9): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yan, J.-K. Luo, K. J. Ritchie, I. Sakai, K. Takeuchi, R. Ren, and D.-E. Zhang Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling Blood, July 1, 2007; 110(1): 305 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Kuo and Z.-F. Chang GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription Mol. Cell. Biol., June 15, 2007; 27(12): 4261 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al. Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches Cancer Res., June 1, 2007; 67(11): 5300 - 5307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ray, S. W. Cowan-Jacob, P. W. Manley, J. Mestan, and J. D. Griffin Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Blood, June 1, 2007; 109(11): 5011 - 5015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Tringali, B. Lupo, L. Anastasia, N. Papini, E. Monti, R. Bresciani, G. Tettamanti, and B. Venerando Expression of Sialidase Neu2 in Leukemic K562 Cells Induces Apoptosis by Impairing Bcr-Abl/Src Kinases Signaling J. Biol. Chem., May 11, 2007; 282(19): 14364 - 14372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nguyen, M. Rahmani, H. Harada, P. Dent, and S. Grant MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825 Blood, May 1, 2007; 109(9): 4006 - 4015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weisberg, L. Catley, R. D. Wright, D. Moreno, L. Banerji, A. Ray, P. W. Manley, J. Mestan, D. Fabbro, J. Jiang, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias Blood, March 1, 2007; 109(5): 2112 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yoshida, F. Yoshida, D. E. Sears, S. M. Hart, D. Ikebe, A. Muto, S. Basu, K. Igarashi, and J. V. Melo Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1 Blood, February 1, 2007; 109(3): 1211 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. U. Birkenkamp, A. Essafi, K. E. van der Vos, M. da Costa, R. C.-Y. Hui, F. Holstege, L. Koenderman, E. W.-F. Lam, and P. J. Coffer FOXO3a Induces Differentiation of Bcr-Abl-transformed Cells through Transcriptional Down-regulation of Id1 J. Biol. Chem., January 26, 2007; 282(4): 2211 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kharas, I. Yusuf, V. M. Scarfone, V. W. Yang, J. A. Segre, C. S. Huettner, and D. A. Fruman KLF4 suppresses transformation of pre-B cells by ABL oncogenes Blood, January 15, 2007; 109(2): 747 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, A. Vales, M.-T. Krauth, K. V. Gleixner, M. Bilban, H. Esterbauer, K. Sonneck, S. Florian, S. Derdak, et al. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells Blood, November 15, 2006; 108(10): 3538 - 3547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. La Rosee, T. Jia, S. Demehri, N. Hartel, P. de Vries, L. Bonham, D. Hollenback, J. W. Singer, J. V. Melo, B. J. Druker, et al. Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib. Clin. Cancer Res., November 1, 2006; 12(21): 6540 - 6546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Griswold, M. MacPartlin, T. Bumm, V. L. Goss, T. O'Hare, K. A. Lee, A. S. Corbin, E. P. Stoffregen, C. Smith, K. Johnson, et al. Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol., August 1, 2006; 26(16): 6082 - 6093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Quintas-Cardama and J. E. Cortes Chronic Myeloid Leukemia: Diagnosis and Treatment Mayo Clin. Proc., July 1, 2006; 81(7): 973 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Goss, K. A. Lee, A. Moritz, J. Nardone, E. J. Spek, J. MacNeill, J. Rush, M. J. Comb, and R. D. Polakiewicz A common phosphotyrosine signature for the Bcr-Abl kinase Blood, June 15, 2006; 107(12): 4888 - 4897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grunebach, V. Mirakaj, V. Mirakaj, M. R. Muller, T. Brummendorf, and P. Brossart BCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia Cancer Res., June 1, 2006; 66(11): 5892 - 5900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Piwocka, S. Vejda, T. G. Cotter, G. C. O'Sullivan, and S. L. McKenna Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling Blood, May 15, 2006; 107(10): 4003 - 4010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wagner, P. Zhang, F. Rosenbauer, B. Drescher, S. Kobayashi, H. S. Radomska, J. L. Kutok, D. G. Gilliland, J. Krauter, and D. G. Tenen Absence of the transcription factor CCAAT enhancer binding protein {alpha} results in loss of myeloid identity in bcr/abl-induced malignancy PNAS, April 18, 2006; 103(16): 6338 - 6343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Nguyen, M. Rahmani, N. Gao, L. Kramer, A. S. Corbin, B. J. Druker, P. Dent, and S. Grant Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2239 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. M. Yong, R. M. Szydlo, J. M. Goldman, J. F. Apperley, and J. V. Melo Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML Blood, January 1, 2006; 107(1): 205 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ma, G. Ruan, Y. Wang, Q. Li, P. Zhu, Y.-Z. Qin, J.-L. Li, Y.-R. Liu, D. Ma, and H. Zhao Two Single-Nucleotide Polymorphisms with Linkage Disequilibrium in the Human Programmed Cell Death 5 Gene 5' Regulatory Region Affect Promoter Activity and the Susceptibility of Chronic Myelogenous Leukemia in Chinese Population Clin. Cancer Res., December 15, 2005; 11(24): 8592 - 8599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hess, D. Bunjes, W. Siegert, R. Schwerdtfeger, G. Ledderose, B. Wassmann, G. Kobbe, M. Bornhauser, A. Hochhaus, A. J. Ullmann, et al. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study J. Clin. Oncol., October 20, 2005; 23(30): 7583 - 7593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, M.-T. Krauth, A. Vales, R. Kondo, S. Derdak, W. F. Pickl, E. Selzer, M. Deininger, B. J. Druker, et al. Low-Level Expression of Proapoptotic Bcl-2-Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Underlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds Cancer Res., October 15, 2005; 65(20): 9436 - 9444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Barnes, D. Palaiologou, E. Panousopoulou, B. Schultheis, A. S.M. Yong, A. Wong, L. Pattacini, J. M. Goldman, and J. V. Melo Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Cancer Res., October 1, 2005; 65(19): 8912 - 8919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gannage, M. Abel, A.-S. Michallet, S. Delluc, M. Lambert, S. Giraudier, R. Kratzer, G. Niedermann, L. Saveanu, F. Guilhot, et al. Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy J. Immunol., June 15, 2005; 174(12): 8210 - 8218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaushansky On the molecular origins of the chronic myeloproliferative disorders: it all makes sense Blood, June 1, 2005; 105(11): 4187 - 4190. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Andreu, E. Lledo, E. Poch, C. Ivorra, M. P. Albero, J. A. Martinez-Climent, C. Montiel-Duarte, J. Rifon, J. Perez-Calvo, C. Arbona, et al. BCR-ABL Induces the Expression of Skp2 through the PI3K Pathway to Promote p27Kip1 Degradation and Proliferation of Chronic Myelogenous Leukemia Cells Cancer Res., April 15, 2005; 65(8): 3264 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Gu, L. Santiago, and B. S. Mitchell Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl Blood, April 15, 2005; 105(8): 3270 - 3277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Aichberger, M. Mayerhofer, M.-T. Krauth, H. Skvara, S. Florian, K. Sonneck, C. Akgul, S. Derdak, W. F. Pickl, V. Wacheck, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides Blood, April 15, 2005; 105(8): 3303 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Turcotte, S. Gauthier, A. Tuite, A. Mullick, D. Malo, and P. Gros A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice J. Exp. Med., March 21, 2005; 201(6): 881 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kharas and D. A. Fruman ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors Cancer Res., March 15, 2005; 65(6): 2047 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Unwin, D. W. Sternberg, Y. Lu, A. Pierce, D. G. Gilliland, and A. D. Whetton Global Effects of BCR/ABL and TEL/PDGFR{beta} Expression on the Proteome and Phosphoproteome: IDENTIFICATION OF THE RHO PATHWAY AS A TARGET OF BCR/ABL J. Biol. Chem., February 25, 2005; 280(8): 6316 - 6326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 Blood, February 15, 2005; 105(4): 1768 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guo, C. Sigua, P. Bali, P. George, W. Fiskus, A. Scuto, S. Annavarapu, A. Mouttaki, G. Sondarva, S. Wei, et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells Blood, February 1, 2005; 105(3): 1246 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kaushansky On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense Hematology, January 1, 2005; 2005(1): 533 - 537. [Full Text] [PDF]
|
|
|
|
|
|
S. Wong, J. McLaughlin, D. Cheng, C. Zhang, K. M. Shokat, and O. N. Witte Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations PNAS, December 14, 2004; 101(50): 17456 - 17461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Deming, Z. T. Schafer, J. S. Tashker, M. B. Potts, M. Deshmukh, and S. Kornbluth Bcr-Abl-Mediated Protection from Apoptosis Downstream of Mitochondrial Cytochrome c Release Mol. Cell. Biol., December 1, 2004; 24(23): 10289 - 10299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fernandez de Mattos, A. Essafi, I. Soeiro, A. M. Pietersen, K. U. Birkenkamp, C. S. Edwards, A. Martino, B. H. Nelson, J. M. Francis, M. C. Jones, et al. FoxO3a and BCR-ABL Regulate cyclin D2 Transcription through a STAT5/BCL6-Dependent Mechanism Mol. Cell. Biol., November 15, 2004; 24(22): 10058 - 10071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, R. Pollock, E. P. Stoffregen, J. A. Keats, O. M. Abdullah, E. M. Moseson, V. M. Rivera, H. Tang, C. A. Metcalf III, R. S. Bohacek, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Blood, October 15, 2004; 104(8): 2532 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams, and D. M. Zisterer Selective Induction of Apoptosis by the Pyrrolo-1,5-benzoxazepine 7-[{Dimethylcarbamoyl}oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia Cells Occurs via the c-Jun NH2-Terminal Kinase-Dependent Phosphorylation and Inactivation of Bcl-2 and Bcl-XL J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors Cancer Res., August 1, 2004; 64(15): 5322 - 5331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia Blood, June 15, 2004; 103(12): 4666 - 4668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kharas, J. A. Deane, S. Wong, K. R. O'Bosky, N. Rosenberg, O. N. Witte, and D. A. Fruman Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells Blood, June 1, 2004; 103(11): 4268 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mayerhofer, S. Florian, M.-T. Krauth, K. J. Aichberger, M. Bilban, R. Marculescu, D. Printz, G. Fritsch, O. Wagner, E. Selzer, et al. Identification of Heme Oxygenase-1 As a Novel BCR/ABL-Dependent Survival Factor in Chronic Myeloid Leukemia Cancer Res., May 1, 2004; 64(9): 3148 - 3154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. La Rosee, K. Johnson, A. S. Corbin, E. P. Stoffregen, E. M. Moseson, S. Willis, M. M. Mauro, J. V. Melo, M. W. Deininger, and B. J. Druker In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines Blood, January 1, 2004; 103(1): 208 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tamura, H. J. Kong, C. Tunyaplin, H. Tsujimura, K. Calame, and K. Ozato ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells Blood, December 15, 2003; 102(13): 4547 - 4554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, P. Bali, E. O'Bryan, L. Fuino, F. Guo, J. Wu, P. Houghton, and K. Bhalla Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells Cancer Res., November 15, 2003; 63(22): 7950 - 7958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Kirschner and K. Baltensperger Erythropoietin Promotes Resistance Against the Abl Tyrosine Kinase Inhibitor Imatinib (STI571) in K562 Human Leukemia Cells Mol. Cancer Res., November 1, 2003; 1(13): 970 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamio, T. Toki, R. Kanezaki, S. Sasaki, S. Tandai, K. Terui, D. Ikebe, K. Igarashi, and E. Ito B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs Blood, November 1, 2003; 102(9): 3317 - 3322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiang, M. Stuible, Y. Chalandon, A. Li, W. Y. Chan, W. Eisterer, G. Krystal, A. Eaves, and C. Eaves Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia Blood, October 15, 2003; 102(8): 2976 - 2984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Goldman and J. V. Melo Chronic Myeloid Leukemia -- Advances in Biology and New Approaches to Treatment N. Engl. J. Med., October 9, 2003; 349(15): 1451 - 1464. [Full Text] [PDF]
|
|
|
|
|
|
S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease PNAS, September 30, 2003; 100(20): 11630 - 11635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ly, A. F. Arechiga, J. V. Melo, C. M. Walsh, and S. T. Ong Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S6 and 4E-BP1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin Cancer Res., September 15, 2003; 63(18): 5716 - 5722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. P. Huntly, F. Guilhot, A. G. Reid, G. Vassiliou, E. Hennig, C. Franke, J. Byrne, A. Brizard, D. Niederwieser, J. Freeman-Edward, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions Blood, September 15, 2003; 102(6): 2205 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wertheim, S. A. Perera, D. A. Hammer, R. Ren, D. Boettiger, and W. S. Pear Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development Blood, September 15, 2003; 102(6): 2220 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. N. Deininger and B. J. Druker Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib Pharmacol. Rev., September 1, 2003; 55(3): 401 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells Cancer Res., August 15, 2003; 63(16): 5126 - 5135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. P. Huntly, A. Bench, and A. R. Green Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia Blood, August 15, 2003; 102(4): 1160 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chien, N. Tidow, E. A. Williamson, L.-Y. Shih, U. Krug, A. Kettenbach, A. C. Fermin, C. M. Roifman, and H. P. Koeffler Characterization of a Myeloid Tyrosine Phosphatase, Lyp, and Its Role in the Bcr-Abl Signal Transduction Pathway J. Biol. Chem., July 18, 2003; 278(30): 27413 - 27420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Corbin, P. L. Rosee, E. P. Stoffregen, B. J. Druker, and M. W. Deininger Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib Blood, June 1, 2003; 101(11): 4611 - 4614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kurzrock, H. M. Kantarjian, B. J. Druker, and M. Talpaz Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics Ann Intern Med, May 20, 2003; 138(10): 819 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Furey and D. Haussler Integration of the cytogenetic map with the draft human genome sequence Hum. Mol. Genet., May 1, 2003; 12(9): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dong, K. Cwynarski, A. Entwistle, F. Marelli-Berg, F. Dazzi, E. Simpson, J. M. Goldman, J. V. Melo, R. I. Lechler, I. Bellantuono, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration Blood, May 1, 2003; 101(9): 3560 - 3567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Roman-Gomez, J. A. Castillejo, A. Jimenez, F. Cervantes, C. Boque, L. Hermosin, A. Leon, A. Granena, D. Colomer, A. Heiniger, et al. Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa J. Clin. Oncol., April 15, 2003; 21(8): 1472 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon, and K. Bhalla Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood, April 15, 2003; 101(8): 3236 - 3239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Mohamed, P. Pemberton, J. Zonder, and C. A. Schiffer The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations Clin. Cancer Res., April 1, 2003; 9(4): 1333 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barbouti, M. Hoglund, B. Johansson, C. Lassen, P.-G. Nilsson, A. Hagemeijer, F. Mitelman, and T. Fioretos A Novel Gene, MSI2, Encoding a Putative RNA-binding Protein Is Recurrently Rearranged at Disease Progression of Chronic Myeloid Leukemia and Forms a Fusion Gene with HOXA9 as a Result of the Cryptic t(7;17)(p15;q23) Cancer Res., March 15, 2003; 63(6): 1202 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker Overcoming Resistance to Imatinib by Combining Targeted Agents Mol. Cancer Ther., March 1, 2003; 2(3): 225 - 226. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, and A. Tefferi Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice Mayo Clin. Proc., March 1, 2003; 78(3): 307 - 317. [Abstract] [PDF]
|
|
|
|
|
|
T. Bumm, C. Muller, H.-K. Al-Ali, K. Krohn, P. Shepherd, E. Schmidt, S. Leiblein, C. Franke, E. Hennig, T. Friedrich, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority Blood, March 1, 2003; 101(5): 1941 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scherr, K. Battmer, T. Winkler, O. Heidenreich, A. Ganser, and M. Eder Specific inhibition of bcr-abl gene expression by small interfering RNA Blood, February 15, 2003; 101(4): 1566 - 1569. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Introduction
The physiologic function of...
B.
/
